» Articles » PMID: 35643729

Diagnostic Value of Multiparametric MRI in Detecting Residual or Recurrent Prostate Cancer After High-intensity Focused Ultrasound

Overview
Specialties Oncology
Urology
Date 2022 Jun 1
PMID 35643729
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the diagnostic performance of follow-up multiparametric MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound (HIFU), and to find other, if any, clinical or radiological predictors.

Materials And Methods: Post-HIFU MRIs of 110 consecutive patients who underwent follow-up biopsies between August 2019 and April 2021 were retrospectively analyzed and the likelihood of recurrence was assessed on a five-point Likert scale by two board-certified uroradiologists. Diagnostic performance of the Likert scale assigned to the post-HIFU MRI was assessed using the follow-up biopsy results as a reference standard. Among the clinical and radiological variables, predictors of the recurrence were examined through logistic regression.

Results: In per-patient and per-sector analyses, Likert scale on post-HIFU MRI showed a sensitivity and specificity of 0.37 and 0.97, and 0.42 and 0.87, respectively, in predicting recurrence. Two patients with high suspicion on MRI required additional treatment to regain biochemical control despite negative biopsies. High suspicion on post-HIFU MRI (odds ratio = 1.74; p < 0.01), and more cancer-positive cores on initial biopsy (odds ratio = 1.25; p = 0.03) were independent predictors of recurrence.

Conclusion: Albeit with low sensitivity, high suspicion on post-HIFU MRI may be clinically important because of its high specificity, especially when considering the possibility of sampling error in biopsies. Patients with a high number of cancer-positive cores at diagnosis should avoid HIFU as they have an increased risk of recurrence.

Citing Articles

Interpreting Prostate Multiparametric MRI: Beyond Adenocarcinoma - Anatomical Variations, Mimickers, and Post-Intervention Changes.

Yilmaz E, Esengur O, Gelikman D, Turkbey B Semin Ultrasound CT MR. 2024; 46(1):2-30.

PMID: 39580037 PMC: 11741936. DOI: 10.1053/j.sult.2024.11.001.


Prostate cancer genotyping for risk stratification and precision treatment.

Kumar A Curr Urol. 2024; 18(2):87-97.

PMID: 39176294 PMC: 11337998. DOI: 10.1097/CU9.0000000000000222.


Role of Perilesional Sampling of Patients Undergoing Fusion Prostate Biopsies.

Lombardo R, Tema G, Nacchia A, Mancini E, Franco S, Zammitti F Life (Basel). 2023; 13(8).

PMID: 37629576 PMC: 10455324. DOI: 10.3390/life13081719.


Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review.

Nicoletti R, Alberti A, Castellani D, Yee C, Zhang K, Poon D Prostate Cancer Prostatic Dis. 2023; 27(4):623-634.

PMID: 37507479 DOI: 10.1038/s41391-023-00699-7.


Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs).

Nicoletti R, Alberti A, Castellani D, Yee C, Zhang K, Poon D Prostate Cancer Prostatic Dis. 2023; 27(4):614-622.

PMID: 37491432 DOI: 10.1038/s41391-023-00698-8.

References
1.
Mottet N, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020; 79(2):243-262. DOI: 10.1016/j.eururo.2020.09.042. View

2.
Guo R, Guo X, Li Y, Bie Z, Li B, Li X . Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis. Int J Clin Oncol. 2021; 26(3):461-484. DOI: 10.1007/s10147-020-01847-y. View

3.
Ghafoor S, Becker A, Stocker D, Barth B, Eberli D, Donati O . Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound. Abdom Radiol (NY). 2020; 45(11):3882-3895. DOI: 10.1007/s00261-020-02577-5. View

4.
Ben Cheikh A, Girouin N, Ryon-Taponnier P, Mege-Lechevallier F, Gelet A, Chapelon J . [MR detection of local prostate cancer recurrence after transrectal high-intensity focused US treatment: preliminary results]. J Radiol. 2008; 89(5 Pt 1):571-7. DOI: 10.1016/s0221-0363(08)71483-5. View

5.
Kim C, Park B, Lee H, Kim S, Kim E . MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol. 2008; 190(5):1180-6. DOI: 10.2214/AJR.07.2924. View